Jade Biosciences, Inc. · NASDAQ:JBIO
Jade Biosciences — Corporate Update (September 2026)
18 slides from Jade Biosciences's corporate update, Sep 30, 2026
Slide 1: JADE301 Conference Call and Webcast
September 30, 2026 JADE301 Conference Call and Webcast NASDAQ: JBIO
Slide 2: Disclaimers
Disclaimers FORWARD LOOKING STATEMENTS Certain statements contained in or made orally during this presentation, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisi
Slide 3: Advancing potentially best-in-class therapies for autoimmune diseases
Advancing potentially best-in-class therapies for COMPANY OVERVIEW autoimmune diseases Well-funded through multiple upcoming milestones; runway into the fourth quarter of 2028 POTENTIAL PROGRAM MOA PRECLINICAL PHASE 1 PHASE 2 PHASE 3 INDICATIONS Candidates designed to maximize clinical JADE101 anti-
Slide 4: JADE301: building on validated IFN-β biology with best-in-disease potential
JADE301: building on validated IFN-β biology with best-in- JADE301 disease potential; rapid path to human data Dermatomyositis: IFN-β: JADE301: Large, underserved opportunity Clinically validated mechanism Disease-modifying approach • Debilitating autoimmune disease • IFN-β is a critical upstream dr
Slide 5: Selective IFN-β blockade and SC dosing position JADE301 for best-in-disease potential
Selective IFN-β blockade and SC dosing position JADE301 JADE301 for best-in-disease potential EFFICACY (PBO-ADJUSTED) PRODUCT WEEK 12 / FURTHEST REPORTED SAFETY DOSING CONVENIENCE MECHANISM · ROUTE · STAGE TIS (MUSCLE) CDASI (SKIN) IVIG (Octagam 10%) ✓ 24.9 / o nd / Boxed warning: thrombosis, renal
Slide 6: Dermatomyositis: Disease Overview and Treatment Paradigm
Dermatomyositis: Disease Overview and Treatment Paradigm 6
Slide 7: Dermatomyositis is a debilitating autoimmune disease affecting ~50K U.S. adults
Dermatomyositis is a debilitating autoimmune disease affecting ~50K U.S. adults A chronic, multisystem disease High impact on daily activities ▪ Affects adults and children, with higher prevalence Potential lung, CV and 58% in women malignancy-related 53% complications experience ▪ 60–80% of severe
Slide 8: Despite treatment advances, DM remains burdensome with incomplete disease control
Despite treatment advances, DM remains burdensome with incomplete disease control ▪ Steroids are used in ~80% of DM patients Therapies Received by ~34K and come with significant side effects Opportunity for a Treated Dermatomyositis Patients targeted, disease- ▪ Treatment depends on severity of clin
Slide 9: IFN-β is a key driver of skin and muscle disease in DM
IFN-β is a key driver of skin and muscle disease in DM Excess IFN-β can amplify inflammation, impair muscle repair and contribute to tissue damage ▪ Type I interferon signaling is markedly overactive in DM skin and muscle ▪ Excess signaling activates immune cells, impairs muscle repair and Epidermal
Slide 10: IFN-β is a clinically validated target for DM based on clinical data of dazukibart
IFN-β is a clinically validated target for DM based on clinical data of dazukibart ▪ Dazukibart Phase 2 data demonstrated best-in- DAZUKIBART PHASE 2 DATA disease improvement in cutaneous disease activity (CDASI), and was well-tolerated MoA anti-IFN-β ▪ Dazukibart is dosed Q4W, IV Status Phase 3 ong
Slide 11: JADE301: IFN-β Neutralizing mAb for Dermatomyositis (DM)
JADE301: IFN-β Neutralizing mAb for Dermatomyositis (DM) 11
Slide 12: Potentially best-in-class properties of JADE301
Potentially best-in-class properties of JADE301 JADE301 Novel anti-IFN-β mAb from a de novo antibody discovery Predicted differentiated SC campaign dosing for patient convenience Binds IFN-β with higher affinity than existing therapies Effector-null fully human Half-life extension through IgG1 Fc va
Slide 13: JADE301 delivered high-affinity, selective and potent IFN-β neutralization in preclinical studies
JADE301 delivered high-affinity, selective and potent IFN-β JADE301 neutralization in preclinical studies SPR Binding to Recombinant Inhibition of IFN-β Inhibition of IFN-β Human IFN-β induced pSTAT induced MX-1 1. 5 100 JADE301 DAZUKIBART* 1.50 1. 5 KD = 11.3 pM KD = 28.180pM 100 M X - 1 E X P R E
Slide 14: JADE301 showed extended half-life and favorable SC bioavailability in NHPs
JADE301 showed extended half-life and favorable SC JADE301 bioavailability in NHPs Preclinical data supports clinical evaluation of infrequent SC dosing ~3× longer IV half-life vs. dazukibart comparator Favorable PK following SC administration MEAN (+SD) CONCENTRATION ( μg/ml) MEAN (+SD) CONCENTRATI
Slide 15: JADE301 Phase 1 healthy volunteer study expected to begin 4Q 2026
JADE301 Phase 1 healthy volunteer study expected to begin JADE301 Q4 2026; interim data anticipated in 2H 2027 Phase 1 Study Design Objectives Phase 1 HV study Placebo-controlled, single ascending-dose study PRIMARY designed to generate key data SC administration in healthy volunteers (N=24) ▪ Safet
Slide 16: JADE301: building on validated IFN-β biology with best-in-disease potential
JADE301: building on validated IFN-β biology with best-in- JADE301 disease potential; rapid path to human data Dermatomyositis IFN-β JADE301 Large, underserved Clinically validated Disease-modifying opportunity mechanism approach Phase 1 HV study expected to initiate in 4Q 2026; interim data anticip
Slide 17: Q&A
Q&A 17
Slide 18: Thank you
Thank you JADEBIOSCIENCES.COM INFO@JADEBIOSCIENCES.COM NASDAQ: JBIO